Current Funded Research
Summary of Current Funded Research
2023 FUNDING CYCLE:
$50,000 (over two years) to UCLA Health
To evaluate EMP2’s (a protein-coding gene) expression in primary acoustic neuroma/vestibular schwannoma samples while also aiming to utilize transcriptomic data to correlate the expression of EMP2 with inflammatory, immune, and angiogenic markers. The research will also evaluate the effects of anti-EMP2 treatment in tumorsphere models.
$25,000 to Mayo Clinic
To continue a previously funded research effort to expand the quality-of-life efforts to translate the VSQOL Index to other languages to enhance participation in and reduce the potential of inequitable access to quality-of-life research. Researchers see translation efforts improving the lives of vestibular schwannoma patients in the U.S. and worldwide by increasing inclusivity in research to comprehensively evaluate the impact of a diagnosis of vestibular schwannoma and its treatment on well-being and quality of life.
2022 FUNDING CYCLE:
$25,000 to Mt. Sinai Medical Center
To assess the feasibility of high-field 7-Tesla (7T) MRI to predict facial nerve location, attenuation, and degree of involvement with respect to the vestibular schwannoma using DTI tractography and compare it to published rates for similar studies using lower-strength magnets.
$24,908 to Washington University in St. Louis
To study a cohort of 1,500+ patients with vestibular schwannoma to better define Quality of Life (QOL) relevant to vestibular schwannoma management.
$25,000 to University of California San Diego Health
To profile and compare the genetic characteristics of latent and growing vestibular schwannomas using RNA and whole exome sequencing.
$25,000 to University of California, San Francisco
To develop a mobile app program with machine-learning enhanced capabilities to guide facial therapy.
AUG 2021
Emory University: $21,002
“Circulating Tumor DNA as a Minimally Invasive Biomarker in Patients with Vestibular Schwannoma.”
AUG 2021
UCLA: $14,528 **COMPLETED**
"Epithelial Membrane Protein 2 as a Biomarker and Therapeutic Target for Vestibular Schwannoma."
AUG 2021
Keck School of Medicine, USC: $25,000
"Ultra-high Field 7T Magnetic Resonance Imaging for Predictive Localization of the Facial Nerve in the Presence of Large Vestibular Schwannoma."
AUG 2020
Mayo Clinic: $24,000 **COMPLETED**
“Development and Validation of a New Disease-Specific Quality of Life Index for Sporadic Vestibular Schwannoma.”
MAY 2019
Keck School of Medicine, USC: $25,000 **COMPLETED**
“Single-Cell RNA Transcriptome and DNE Copy Number Variation Sequencing of Vestibular Schwannoma.”